Shares of Stoke Therapeutics (NASDAQ:STOK) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price objective of $39.00 for the company and are anticipating that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Stoke Therapeutics an industry rank of 79 out of 256 based on the ratings given to related companies.

STOK has been the topic of a number of research analyst reports. Canaccord Genuity initiated coverage on shares of Stoke Therapeutics in a research report on Monday, July 15th. They set a “buy” rating and a $44.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics in a research report on Monday, July 15th. They set an “overweight” rating and a $34.00 price objective on the stock. Cowen restated a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, August 15th. Finally, Credit Suisse Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $35.00 target price on the stock.

Shares of STOK stock traded down $2.96 on Monday, reaching $23.63. 247,600 shares of the company were exchanged, compared to its average volume of 165,416. The firm has a 50-day simple moving average of $30.57. Stoke Therapeutics has a one year low of $22.01 and a one year high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.58). As a group, research analysts forecast that Stoke Therapeutics will post -2.24 EPS for the current year.

In other Stoke Therapeutics news, major shareholder Apple Tree Partners Iv, L.P. bought 1,388,889 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were bought at an average price of $18.00 per share, for a total transaction of $25,000,002.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Rtw Investments, Lp bought 555,556 shares of the stock in a transaction that occurred on Wednesday, June 19th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $10,000,008.00. The disclosure for this purchase can be found here.

Large investors have recently bought and sold shares of the business. Platinum Investment Management Ltd. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $29,000. Victory Capital Management Inc. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $73,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $88,000. Morgan Stanley purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $104,000. Finally, KCL Capital L.P. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at about $292,000. Hedge funds and other institutional investors own 43.43% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

See Also: Growth Stocks

Get a free copy of the Zacks research report on Stoke Therapeutics (STOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.